HPV vaccine efficacy and perspectives - Part B: Impact of HPV vaccine on cancer outcomes, how soon?
Monday, December 3, 2018
Main Scientific Session
•
MSS 01b
•
8:45 AM
>
9:45 AM
•
HPV vaccine efficacy and perspectives - Part B: Impact of HPV vaccine on cancer outcomes, how soon?
•
Auditorium I
HPV vaccines have been in use in populations for 13 years, with follow up of trial participants ahead of these cohorts. There is strong evidence of vaccine effectiveness against HPV infections and pre-cancerous lesions and it is timely to consider how soon population evidence of vaccine impact against cancer outcomes will emerge. This is particularly relevant as the WHO start to gather the evidence and develop a strategy to support a global campaign for elimination of cervical cancer as a public health problem. In this session we will hear from countries who started follow-up programs early on and also review the global situation.
8:45 AM
•
MSS 01b-01
•
If we do nothing....what is the projected burden of HPV associated cancers if we fail to deliver HPV vaccines or scale up screening?
>
F.
Freddie
BRAY
8:55 AM
•
MSS 01b-02
•
Predicting declines in cervical cancer due to vaccination: the global perspective
>
K.
Kate
SIMMS
9:05 AM
•
MSS 01b-03
•
Cervical cancer rates in Australia: predicting the declines due to vaccination and screening policy
>
M.
Megan
SMITH
9:15 AM
•
MSS 01b-04
•
When will the UK start to see declines in cervical cancer due to vaccination?
>
M.
Mark
JIT
9:25 AM
•
MSS 01b-05
•
Is the US starting to see declines in cervical cancer due to vaccination?
>
M.
Mona
SARAIYA
9:35 AM
•
MSS 01b-06
•
Discussion
|